Posted on by lowes1

Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients

Condition:   Asthma
Interventions:   Biological: Mepolizumab 100mg;   Drug: Placebo
Sponsor:   GlaxoSmithKline
Not yet recruiting – verified September 2015

View full post on ClinicalTrials.gov: asthma | received in the last 14 days

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.